Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Roche's Cobas Mutation Test For Lung Cancer Gets

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
SAE Member Profile
 
Followed By 2
Posts 564
Boards Moderated 0
Alias Born 08/06/09
160x600 placeholder
Sarepta posts positive data from SRP-9001 DMD study Seeking Alpha - 5/18/2021 9:08:01 AM
FDA OKs emergency use of Roche's cobas SARS-CoV-2 test in asymptomatic people Seeking Alpha - 5/18/2021 1:35:11 AM
FDA panel votes to keep indications for Merck, Roche bladder cancer drugs Seeking Alpha - 4/30/2021 7:58:15 AM
FDA panel votes to maintain breast cancer indication for Roche's Tecentriq Seeking Alpha - 4/27/2021 5:26:34 PM
Roche Gets FDA Approval for Cancer-Treatment Test Dow Jones News - 4/23/2021 6:47:00 AM
Roche Q1 sales beats forecast, 2021 outlook confirmed Seeking Alpha - 4/21/2021 5:35:48 AM
Roche Holding beats on revenue; 2021 outlook confirmed Seeking Alpha - 4/21/2021 4:43:18 AM
Roche Backs 2021 Views After 1Q Sales Fall Slightly Dow Jones News - 4/21/2021 1:54:00 AM
Novartis to help produce Roche's Actemra Seeking Alpha - 4/15/2021 5:38:12 AM
Roche’s Evrysdi continues to improve motor function, survival in babies with spinal muscular atrophy Seeking Alpha - 4/15/2021 3:11:36 AM
Novartis Enters Agreement With Roche on Production of the Latter's Drug Dow Jones News - 4/15/2021 2:14:00 AM
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
SAE   Tuesday, 12/06/11 12:18:56 PM
Re: None
Post # of 252 

Roche's Cobas Mutation Test For Lung Cancer Gets CE Mark

Roche Holding AG (ROG.VX) Thursday said its cobas EGFR Mutation Test is now CE marked for commercial availability in Europe and other countries that recognize CE mark.

MAIN FACTS:


- The cobas EGFR Mutation Test is a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who harbor mutations in the EGFR (epidermal growth factor receptor) gene and who may benefit from treatment with anti-EGFR tyrosine kinase inhibitors such as Roche's Tarceva (erlotinib).

- Tarceva, an oral EGFR inhibitor, was approved by the European Commission in September as first-line monotherapy in people with locally advanced or metastatic NSCLC with EGFR activating mutations.

- It is estimated that 10-30 percent of patients with NSCLC have tumors with EGFR activating mutations which are highly responsive to EGFR inhibitors such as Tarceva1.

- Treatment with this medicine has been shown to more than triple the number of patients whose tumours shrink (response rate) and to nearly double the time patients live without their disease progressing (progression free survival - PFS) compared to chemotherapy.

-Zurich Bureau, Dow Jones Newswires, +41 43 443 80 47; zurichdjnews@dowjones.com



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences